New drug IBI3003 enters first human trials for Hard-to-Treat multiple myeloma
Disease control
Not yet recruiting
This early-phase trial is testing a new drug called IBI3003 in about 360 people with multiple myeloma that has returned or no longer responds to standard treatments. The study has two parts: first, finding the safest and most effective dose, and then testing how well it works. Pa…
Phase: PHASE1, PHASE2 • Sponsor: Fortvita Biologics (USA)Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC